Travere Therapeutics Inc. (TVTX) announced that new data further demonstrates the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforces its potential in focal segmental glomerulosclerosis (FSGS).
The data presented at the American Society of Nephrology (ASN) Kidney Week 2024 provided additional evidence that FILSPARI is effective across all subgroups of IgAN patients studied to-date, and that it achieved significant levels of complete remission when used in newly diagnosed patients.
Travere also shared initial data showing that FILSPARI safely induced further proteinuria reduction when used with SGLT2 inhibitors or steroids, supportive of the flexibility to be used in combination with other medicines as needed.
Furthermore, the company shared data exploring a subgroup of genetic FSGS patients in DUPLEX Study. Genetic FSGS patients are often treatment resistant so the significant reductions in proteinuria and benefit on outcomes reported in this group are very encouraging.
The company noted that nearly 60% of patients with IgA nephropathy (IgAN) in the SPARTAN Study achieved complete remission. This outcome was observed when FILSPARI was used as a first-line treatment.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.